Skip to content

Legal status · United Kingdom

Is 17-DMAG legal in the United Kingdom?

Written by Reviewed Sep 2026

Not approvedLongevityHuman studies cited: 4

Direct answer

No. 17-DMAG is not approved for any medical use in the United Kingdom; its classification is "Investigational, not licensed". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.

17-DMAG in the United Kingdom at a glance

ClassificationInvestigational, not licensed
MHRA approval statusNot approved by MHRA; investigational
Human studies cited4 of 7 citations on the profile
ReviewedSep 2026

Classification and note come from the 17-DMAG profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.

What this means

  • 01

    17-DMAG is being studied in registered clinical trials but has not received MHRA marketing approval in the United Kingdom.

  • 02

    Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

  • 03

    Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What 17-DMAG is

An HSP90 inhibitor that failed to extend mouse lifespan by the Interventions Testing Program's protocol test and showed a 7 to 9 percent male median gain by the Gehan test, and that extended healthspan in a progeroid mouse as one of the first senolytics identified. In people it went through oncology phase 1 trials with cardiac, ocular and one treatment-related death as dose-limiting events, and development stopped around 2010.

17-DMAG (alvespimycin) is a water-soluble derivative of geldanamycin that inhibits heat shock protein 90, the chaperone that stabilises many oncogenic signalling proteins. It was developed as a cancer drug by Kosan Biosciences and then Bristol-Myers Squibb, reached phase 1 in solid tumours, acute myeloid leukaemia and HER2-positive breast cancer, and was not taken further.

Mechanism: 17-DMAG binds the ATP pocket of HSP90 and blocks its chaperone cycle, sending client proteins such as CDK4, HER2, AKT and mutant kinases to proteasomal degradation and inducing HSP70 as a compensatory response. In the human phase 1 trials, HSP72 induction in blood cells was detectable from 20 mg/m2 and client protein depletion at 80 mg/m2, so the target was engaged at tolerated doses.

Regulatory history: Investigational, never approved. Oncology phase 1 trials completed 2004 to 2012; a phase 2 in HER2-positive breast cancer was terminated after 4 patients; no trial registered since 2010. The lifespan signal is a Gehan-only reanalysis result in male mice; the healthspan result is in a progeroid mouse model.

How MHRA treats this kind of product

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for 17-DMAG at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

17-DMAG in other countries

Frequently asked questions

Is 17-DMAG legal in the United Kingdom?

No. 17-DMAG is not approved for any medical use in the United Kingdom; its classification is "Investigational, not licensed". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.

Can I buy 17-DMAG in the United Kingdom?

No approved product exists to buy. In the United Kingdom 17-DMAG is classified as "Investigational, not licensed", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.

Is 17-DMAG MHRA approved?

No. In the United Kingdom 17-DMAG is classified as "Investigational, not licensed", which is not a MHRA marketing approval. For comparison, the US FDA status is: Investigational, never approved. Oncology phase 1 trials completed 2004 to 2012; a phase 2 in HER2-positive breast cancer was terminated after 4 patients; no trial registered since 2010. The lifespan signal is a Gehan-only reanalysis result in male mice; the healthspan result is in a progeroid mouse model.. On the evidence, 4 human studies are cited on its profile.

Related compounds in the United Kingdom

Full research profile

Mechanism, cited studies, FDA status and the full legal summary for 17-DMAG live on its compound profile.

17-DMAG profile

This page is general information about the regulatory status of 17-DMAG in the United Kingdom, current as of Sep 2026. It is not legal advice, and classifications change; check Medicines and Healthcare products Regulatory Agency directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.